Q-omics provides the consensus-scored LINC01300 profile across patient tissues and cancer cell-line models. LINC01300 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, LINC01300 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LINC01300 RNA expression shows 8,484 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, THCA, and TGCT as cancer lineages where LINC01300 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01300 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01300 survival associations across molecular data types. LINC01300 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01300 RNA expression–survival associations across cancer types. High LINC01300 expression shows unfavorable associations in DLBC, KIRC, UVM and LUAD, but favorable associations in CHOL and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for LINC01300 RNA expression.
This table summarizes LINC01300 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01300. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01300 shows lower tumor expression in THCA, UCEC, KICH, BRCA and COAD and higher tumor expression in PAAD. The THCA box plot shows higher LINC01300 RNA expression in normal versus tumor tissue (log2 FC = −0.163, t-test p = .002).
This table shows molecular features associated with LINC01300 in patient tissues and cancer cell lines. In patient samples, LINC01300 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
